Neurofibromatosis type 2.
Sathornsumetee
S
S
Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. . satho001@mc.duke.edu
DesJardins
A
A
Reardon
D A
DA
Rich
J N
JN
Vredenburgh
J J
JJ
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D003056:Cochlear Nerve / Q000473:pathology* / Q000503:physiopathology; D005260:Female; D007839:Functional Laterality / Q000502:physiology; D006319:Hearing Loss, Sensorineural / Q000209:etiology*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D016518:Neurofibromatosis 2 / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D009464:Neuroma, Acoustic / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016896:Treatment Outcome; D014725:Vestibular Nerve / Q000473:pathology* / Q000503:physiopathology
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D006918:Hydroxyurea